Bone Biologics Corporation (BBLG)
Bone Biologics Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Burlington, MA, US. The stock last traded at $0.50, up 0.98% on the session, giving a market capitalisation of $897,948. On trailing twelve-month figures it carries a trailing P/E of -0.27, a net margin of 0.0%. Its beta of 0.50 implies it has historically moved less than the broad market.
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
Bone Biologics Corporation is most often compared with the following Healthcare names: